India, Jan. 13 -- Karyopharm Therapeutics Inc. (KPTI), Monday announced preliminary fourth-quarter and full-year 2024 total revenue and U.S. XPOVIO net product revenue estimates.
The company expects total revenue, which includes license and royalty revenue from partners, to be about $30 million for the fourth quarter 2024 and around $145 million for the full year 2024.
The U.S. XPOVIO net product revenue to be about $29 million for the fourth quarter 2024 and around $113 million for the full year 2024.
The company also announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025.
"Our top strategic objective for 2025 is to deliver on the transformative opportuni...